Zelnecirnon
Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research[1].
Product Specifications
CAS Number
2366152-15-8
Product Name Alternative
RPT193
UNSPSC
12352005
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/zelnecirnon.html
Purity
99.71
Solubility
DMSO : 100 mg/mL (ultrasonic) |Methanol : 250 mg/mL (ultrasonic)
Smiles
C[C@H](C1=C(C=C(C=C1)Cl)Cl)NC2=NC(N3CC([C@@H]4CN([C@H]5C[C@@](C)(C5)C(O)=O)CCC4)C3)=NC(C)=C2Cl
Molecular Formula
C27H34Cl3N5O2
Molecular Weight
566.95
References & Citations
[1]Bissonnette R, et al. RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis[C]//EXPERIMENTAL DERMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021, 30: 40-41.|[2]Cheng L, et al. Development and first-in-human characterization of a potent oral CCR4 antagonist for the treatment of atopic dermatitis[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2020, 140 (7) : S77-S77.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CCR4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY419689 100 µg
Casein Kinase 1 alpha (CSNK1A1) (NM_001892) Human Over-expression Lysate
Sign In for Pricing
View Details 